New developments in neurendocrine tumours

Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial Carcinoma

Professor Petros Grivas shares his insights on the AMBASSADOR study.

Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer

Professor Petros Grivas shares his insights on the NIAGARA study.

Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases

Professor Giampaolo Bianchini shares his insights on the DESTINY-Breast12 study.

Breast cancer, metastatic highlights of the ESMO 2024 Congress

Professor Giampaolo Bianchini shares his insights on the breast cancer metastatic highlights of the ESMO 2024 Congress.

RCC highlights of ESMO 2024 Congress

Professor Camillo Porta shares his insights on the RCC highlights of the ESMO 2024 Congress. He talks about studies like TiNivo-2, CONTACT-03, SUNNIFORECAST and LITESPARK-005.

Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor

Professor Oliver Sartor shares his insights on the SPLASH study.

Prostate Cancer highlights of ESMO 2024 Congress

Professor Oliver Sartor shares his insights on the prostate cancer highlights of the ESMO 2024 Congress.

Radiation therapy for breast cancer can be safely shortened by changing technique

Professor Sofia Rivera shares his insights at ESMO 2024 about the phase three HypoG-01 study looking at hypofractionated radiation therapy for breast cancer.

Melanoma highlights of the ESMO 2024 Congress

Professor Jessica Hassel shares his insights on the melanoma highlights of the ESMO 2024 Congress. She talks about studies like CheckMate067, CheckMate 76K, Keynote-006, Keynote-716 and NADINA.

Quadruplet therapy is becoming the new standard of treatment - Multiple myeloma highlights at ESMO2024

Professor Xavier Leleu shares his insights about the importance of quadruple therapy in multiple myeloma.

Lymphoma highlights of the ESMO 2024 Congress

Professor Maria Gomes da Silva shares his insights on the lymphoma highlights of the ESMO 2024 Congress. She talks about topics like bispecific antibodies, CAR-T cell therapy, MCL and CLL.

LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib + Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma

Professor Josep Llovet discusses the results of LEAP-012 Study which he presented at ESMO 2024.

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Professor Domenica Lorusso presented the overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer.

Lung cancer interception: New approaches to lung cancer screening and prevention

Professor Jianjun Zhang shares his thoughts on lung cancer screening and prevention.

Genitourinary tumours, non-prostate highlights of the ESMO 2024 Congress

Professor Aristotelis Bamias shares his thoughts on genitourinary tumours highlights of the ESMO 2024 Congress.